Corixa allergy drug proves safe
The toll-like receptor 4 (TLR4) agonist, CRX-675, was given to participants intranasally prior to stimulation with ragweed allergen. Although the primary objective of this clinical trial was to
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.